Indeed, a recent and successful phase I/II clinical trial using the pan-NOS inhibitor L-NMMA combined with docetaxel and low-dose aspirin showed complete or partial remission in patients with drug-resistant TNBC and locally advanced breast cancer who had otherwise exhausted treatment options (12). This evidence concerns the gene NOS2 and breast cancer.